RXi Pharmaceuticals Corp., of Worcester, Mass., reported its collaboration with miRagen Therapeutics Inc., of Boulder, Colo., demonstrated that RXi's self-delivering rxRNA (sd-rxRNA) technology could be used in vitro to enhance the activity of a microRNA of interest to miRagen.